OBJECTIVE: To probe into the clinical efficacy of Bufeizhuyu decoction in treatment of chronic obstructive pulmonary disease（ COPD） in stable stage. METHODS: 80 patients with COPD in stable stage admitted into Pudong Hospital of Traditional Chinese Medicine from Jan. 2017 to Oct. 2018 were selected and divided into observation group and control group via random number table

with 40 cases in each group. Both groups were given conventional therapy of western medicine

in addition

the observation group was treated with Bufeizhuyu decoction

both groups were treated for 2 months. The clinical efficacy

symptom scores

indices of pulmonary function [the percentage of forced expiratory volume in 1 s（ FEV

1

） accounted for expected value（ FEV

1

%）

FEV

1

/forced vital capacity（ FVC）

the percentage of peak expiratory flow accounted for expected value（ PEF%） ] and blood gas analysis [arterial partial pressure of oxygen（ PaO

2

）

arterial partial pressure of carbon dioxide（ PaCO

2

） and arterial oxygen saturation（ SaO

2

） ]

serum inflammatory factors [tumor necrosis factor-α（ TNF-α） and interleukin-8（ IL-8） ]

and incidences of adverse drug reactions of two groups before and after treatment were observed. RESULTS: The total effective rate of observation group was 92. 50%（ 37/40）

which was significantly higher than that of the control group（ 75. 00%

30/40）

with statistically significant difference（ P

<

0. 05）. After treatment

the symptom scores（ cough

expectoration

gasp

dyspnea

cyanosis and wheezing） of both groups were significantly lower than those of before treatment

and those of the observation group were significantly lower than the control group

with statistically significant differences（ P

<

0. 05）; the FEV

1

%

FEV

1

/FVC and PEF% of both groups were significantly higher than those of before treatment

and those of the observation group were significantly higher than the control group

with statistically significant differences（ P

<

0. 05）; the PaO2 and SaO2 levels of both groups were significantly higher than those of before treatment

while the PaCO2 level was significantly lower

the PaO2

PaCO2 and SaO2 levels of observation group were significantly better than those of the control group

with statistically significant differences（ P

<

0. 05）; the serum TNF-α and IL-8 levels of both groups were significantly lower than those of before treatment

and those of the observation group were significantly lower than the control group

with statistically significant differences（ P

<

0. 05）. Adverse drug reactions were few and mild in both groups. CONCLUSIONS: The efficacy of Bufeizhuyu decoction combined with conventional therapy in treatment of COPD in stable stage is remarkable

which can effectively promote the remission of clinical symptoms and physical signs

improve pulmonary function and arterial blood gases

inhibit inflammatory reactions.